Education
About Us
Working with TipRanks
Follow Us
Bioxcel Therapeutics Inc (BTAI)
NASDAQ:BTAI
BTAI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.17 - $13.28
Previous CloseN/A
Volume1.10M
Average Volume (3M)5.53M
Market Cap
$51.47M
Enterprise Value$104.56M
Total Cash (Recent Filing)$17.43M
Total Debt (Recent Filing)$108.69M
Price to Earnings (P/E)―
Beta2.50
Next Earnings
Nov 13, 2025EPS Estimate
-1.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.45
Shares Outstanding19,646,801
10 Day Avg. Volume1,525,012
30 Day Avg. Volume5,529,935
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.16
Price to Sales (P/S)6.69
P/FCF Ratio-0.21
Enterprise Value/Market Cap2.03
Enterprise Value/Revenue120.46
Enterprise Value/Gross Profit-79.45
Enterprise Value/Ebitda-2.66
Forecast
1Y Price Target
$8.25Price Target Upside222.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessThe SERENITY At-Home pivotal Phase 3 trial yielded positive exploratory efficacy data, demonstrating continued effects and consistent benefit with repeat dosing of BXCL501.
Market OpportunitySafety data could pave the way for at-home use of BXCL501, which presents a significant opportunity as the need for safe and efficacious acute treatments for agitation remains very high.
Regulatory ApprovalBXCL501 was previously granted Fast Track Designation, and there are no FDA-approved therapies for the acute treatment of agitation in the at-home setting, suggesting a favorable regulatory outlook.
Bears Say
Market Penetration ChallengesSignificant investment is needed to effectively penetrate the larger than anticipated addressable market of agitation episodes.
Somnolence ConcernsThere are concerns about the somnolence rate in both placebo and active arms of the trial.
Unanswered QuestionsSeveral questions yet to be answered ahead of the supplemental New Drug Application submission.
Bioxcel Therapeutics News
BTAI FAQ
What was Bioxcel Therapeutics Inc’s price range in the past 12 months?
Bioxcel Therapeutics Inc lowest stock price was $1.17 and its highest was $13.28 in the past 12 months.
What is Bioxcel Therapeutics Inc’s market cap?
Bioxcel Therapeutics Inc’s market cap is $51.47M.
When is Bioxcel Therapeutics Inc’s upcoming earnings report date?
Bioxcel Therapeutics Inc’s upcoming earnings report date is Nov 13, 2025 which is in 43 days.
How were Bioxcel Therapeutics Inc’s earnings last quarter?
Bioxcel Therapeutics Inc released its earnings results on Aug 12, 2025. The company reported -$2.45 earnings per share for the quarter, missing the consensus estimate of -$1.858 by -$0.592.
Is Bioxcel Therapeutics Inc overvalued?
According to Wall Street analysts Bioxcel Therapeutics Inc’s price is currently Undervalued.
Does Bioxcel Therapeutics Inc pay dividends?
Bioxcel Therapeutics Inc does not currently pay dividends.
What is Bioxcel Therapeutics Inc’s EPS estimate?
Bioxcel Therapeutics Inc’s EPS estimate is -1.02.
How many shares outstanding does Bioxcel Therapeutics Inc have?
Bioxcel Therapeutics Inc has 19,646,801 shares outstanding.
What happened to Bioxcel Therapeutics Inc’s price movement after its last earnings report?
Bioxcel Therapeutics Inc reported an EPS of -$2.45 in its last earnings report, missing expectations of -$1.858. Following the earnings report the stock price went up 6.25%.
Which hedge fund is a major shareholder of Bioxcel Therapeutics Inc?
Among the largest hedge funds holding Bioxcel Therapeutics Inc’s share is Driehaus Capital Management LLC. It holds Bioxcel Therapeutics Inc’s shares valued at 0.
Bioxcel Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.25 (222.27% Upside)
$8.25 (222.27% Upside)
Blogger Sentiment
Bullish
BTAI Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 1.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 0.9%
Last 30 Days ▲ 0.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-72.83%
12-Months-Change
Fundamentals
Return on Equity
82.91%
Trailing 12-Months
Asset Growth
-60.59%
Trailing 12-Months
Company Description
Bioxcel Therapeutics Inc
Bioxcel Therapeutics, Inc. (BTAI) is a biopharmaceutical company that leverages artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology. The company is focused on discovering, developing, and commercializing innovative therapies through its proprietary AI platform designed to identify new therapeutic opportunities. Their core areas include treatments for acute agitation in patients with neuropsychiatric disorders and therapies targeting rare forms of cancer.
BTAI Stock 12 Month Forecast
Average Price Target
$8.25
▲(222.27% Upside)
Technical Analysis
Traws Pharma
―
Relmada Therapeutics
―
Citius Pharmaceuticals
―
Hookipa Pharma
―
Athira Pharma
―
Ownership Overview
3.96% Insiders
0.59% Mutual Funds
2.74% Other Institutional Investors
92.42% Public Companies and
Individual Investors